A Comparative Study of the Clinical Effects of Targeted Treatments with Nilaparib and Olaparib on Recurrent Ovarian Cancer

作者：Tang, Zhenli; Xin, Demei; Liu, Wei; Yan, Bing; Liu, Rui^*

来源：JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2023, 37(3): 1679-1684.

DOI：10.23812/j.biol.regul.homeost.agents.20233703.166

• Niraparib
• Olaparib
• recurrent ovarian cancer
• clinical effects

Objective: To study and compare the clinical effects of targeted treatments with Nilaparib and Olaparib on recurrent ovarian cancer. Methods: A total of 98 patients with recurrent ovarian cancer who were diagnosed and treated in our hospital from February 2019 to July 2021 were enrolled and randomly assigned to group A and group B, with 49 patients in each group. Patients in both groups received combined chemotherapy regimen of paclitaxel and cisplatin (TP). In addition, group A received Nilaparib while group B was treated with Olaparib. The two groups were compared with respect to clinical therapeutic effects and safety of medication. Results: The objective response rate (ORR) and disease control rate (DCR) were significantly higher in group A than in group B (p < 0.05). After treatment, the serum level of cancer antigen 125 (CA125) in group A was markedly lower than that in group B (p < 0.05). However, there were no significant differences in total incidence of adverse reactions between the two groups. Conclusions: Nilaparib produced a relatively better therapeutic effect in the treatment of recurrent ovarian cancer, when com-pared with Olaparib, and it decreased serum level of CA125. Therefore, the overall clinical effect of targeted treatment with Niraparib on recurrent ovarian cancer was better than that of Olaparib.

• 单位
  哈尔滨医科大学